MohammedMahmoudMilhemMD

Clinical Trials

• Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat Start of enrollment: 2009 Dec 01

  Terminated

  Phase 1, Phase 2

• Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas Start of enrollment: 2010 Sep 01

  Completed

  Phase 1

• Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free Start of enrollment: 2010 Jun 01

  Completed

  Phase 2

• Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Start of enrollment: 2011 May 01

  Terminated

  Phase 2, Phase 3

• Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma Start of enrollment: 2011 Apr 01

  Completed

  Phase 2

• Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors Start of enrollment: 2011 Jun 01

  Unknown status

  Phase 1

• HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Start of enrollment: 2012 Aug 01

  Terminated

  Phase 4

• Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery Start of enrollment: 2012 Aug 20

  Completed

  Phase 2

• Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery Start of enrollment: 2013 Jul 31

  Completed

  Phase 2

• HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma Start of enrollment: 2013 May 01

  Terminated

  Phase 4

• Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib Start of enrollment: 2013 Oct 01

  Terminated

  Phase 1

• Ketogenic Diet Phase 1 for Head & Neck Cancer Start of enrollment: 2014 Jan 01

  Terminated

  Not Applicable

• Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma Start of enrollment: 2014 Jun 13

  Completed

  Phase 2

• Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis Start of enrollment: 2014 Mar 21

  Completed

  Phase 3

• Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2013 Oct 18

  Completed

  Phase 2

• Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases Start of enrollment: 2015 Feb 01

  Terminated

  Phase 2

• TVEC and Preop Radiation for Sarcoma (4 ml Dose) Start of enrollment: 2015 Jul 13

  Completed

  Phase 1, Phase 2

• NIAGEN and Persistent Chemotherapy-Induced Peripheral Neuropathy Start of enrollment: 2020 Feb 19

  Active, not recruiting

  Phase 2

• Chlorpromazine and Standard of Care in Glioblastoma Start of enrollment: 2022 Jan 28

  Active, not recruiting

  Phase 1

  Roles: Sponsor-Investigator, Contact, Principal Investigator

• Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial Start of enrollment: 2017 Jul 18

  Active, not recruiting

  Phase 1

  Roles: Sponsor-Investigator, Principal Investigator, Contact

• Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot) Start of enrollment: 2020 Nov 24

  Recruiting

  Early Phase 1

  Roles: Principal Investigator, Sponsor-Investigator, Contact

• Palbociclib and Pembrolizumab in Undifferentiated Pleomorphic Sarcoma (UPS) Start of enrollment: 2024 Feb 01

  Recruiting

  Phase 1

  Roles: Contact, Sponsor-Investigator, Principal Investigator

• Join now to see all